DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT05779644

UnknownPhase NA

Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus

Lead sponsor

RenJi Hospital

Assets

Liraglutide / Semaglutide

Listed sites

1

Recruiting sites

1

Enrollment

300

estimated

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criteria

•BMI ≥24•HbA1c 6-9%

Primary endpoints

•Blood glucose•Blood insulin•Total cholesterol, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05779644
Org study IDIIT-2022-0245

Timeline

Milestones

Study start2023-02-23actual
Study first posted2023-03-22actual
Last update posted2023-05-16actual
Primary completion2025-02-23estimated
Study completion2025-02-23estimated

Assets

Investigational agents

LiraglutideSemaglutide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Aged 18-65 years old
•BMI≥24kg/㎡, or waist circumference: > 85cm (for male) or > 80cm (for female)
•Has been diagnosed with type 2 diabetes mellitus
•Good blood glucose control in recent three months: random blood sugar < 14mmol/L and HbA1c 6-9%
•Not received any drugs affecting glucose and lipid metabolism or weight loss surgery in the past one month

Exclusion criteria

•Abnormal weight gain caused by other endocrine diseases
•Severe metabolic diseases, such as diabetic ketoacidosis, hypertonic hyperglycemia
•Type 1 diabetes or other special types of diabetes
•Used drugs affecting glycolipid metabolism in the past three months
•Severe bleeding tendency that unable to complete venous blood collection
•Patients with MRI contraindications
•Severe renal insufficiency or severe liver insufficiency
•Patients with advanced malignant tumors
•Serious cardiovascular and cerebrovascular diseases
•Rheumatic and immune diseases
•Pregnant and lactating women

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers
3
Weight & body composition
2
Glycemic / diabetes
2

Weight & body composition

2 endpoints
Primary/protocol endpoint

Weight

Time frame:The twelfth week of treatment

change from baseline, improvement

Primary/protocol endpoint/low confidence

Abdominal fat distribution

Time frame:The twelfth week of treatment

change from baseline, improvement

Glycemic / diabetes

2 endpoints
Primary/protocol endpoint/low confidence

Blood glucose

Time frame:The twelfth week of treatment

descriptive, improvement

Primary/protocol endpoint

Blood insulin

Time frame:The twelfth week of treatment

descriptive, improvement

Cardiometabolic biomarkers

3 endpoints
Primary/protocol endpoint

Total cholesterol

Time frame:The twelfth week of treatment

Total cholesterol, change

change from baseline, improvement

LOINC 2093-3

Primary/protocol endpoint

Triglyceride

Time frame:The twelfth week of treatment

Triglycerides, change

change from baseline, improvement

LOINC 2571-8

Primary/protocol endpoint/low confidence

Lipoprotein

Time frame:The twelfth week of treatment

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.